DiGirolamo Wants Deadly New Pain Killer Zohydro Added to List of Banned Drugs
HARRISBURG – In his ongoing fight to help prevent drug addiction and overdoses, Rep. Gene DiGirolamo (R-Bucks) is proposing legislation that would add a powerful and deadly pain killer, Zohydro, to the Schedule I list of controlled substances.

“The heroin and opiate epidemic in this state – and across the country – has reached into nearly every community with overdose deaths being reported daily, and more needs to be done to get opioid-based pain killers off the streets so fewer people become addicted,” DiGirolamo said. “Once individuals no longer can access the pain killers, they turn to heroin to get their high. This just fuels the addiction.”

Zohydro is a pure formulation of hydrocodone that is not diluted, is not tamper resistant and contains five to 10 times more of the heroin-like opioid than any drug produced. It was recently approved by the Food and Drug Administration (FDA) against the recommendations of its own medical advisory board.

DiGirolamo’s legislation, which is expected to be introduced soon, calls for Zohydro to be included in Schedule I of the Controlled Substance, Drug, Device and Cosmetics Act until such time as the manufacturer reformulates the drug to be tamper resistant. He said that drugs on this list have no medical use and are forbidden to be sold for any legal reason.

Under Pennsylvania law, Schedule I drugs are rated for the highest potential for abuse and generally have no known medical use in the U.S. Pennsylvania Schedule I drugs include substances such as heroin and LSD.

“Fatal drug overdoses have risen dramatically in the recent past, and without action to protect the public, Zohydro will surely contribute to more deadly overdoses,” DiGirolamo added.

The drug has already been banned in Massachusetts.

The legislation is expected to be referred to the House Human Services Committee for consideration.

Representative Gene DiGirolamo
18th District
Pennsylvania House of Representatives

Media Contact: Jennifer Keaton
GeneDiGirolamo.com / Facebook.com/GeneDiGirolamo